Fig. 2: 2nd PFS (a) and 2nd OS (b) according to treatment received after progression to first-line FOLFOXIRI/Bev.
Bev bevacizumab, CI confidence interval.
Fig. 2: 2nd PFS (a) and 2nd OS (b) according to treatment received after progression to first-line FOLFOXIRI/Bev. | British Journal of Cancer
